## Chun-Hung Liu : Assouad-Nagata dimension of minor-closed metrics

- Mathematical Biology ( 81 Views )Assouad-Nagata dimension addresses both large-scale and small-scale behaviors of metric spaces and is a refinement of Gromov’s asymptotic dimension. A metric space is a minor-closed metric if it is defined by the distance function on the vertices of an edge-weighted graph that satisfies a fixed graph property preserved under vertex-deletion, edge-deletion, and edge-contraction. In this talk, we determine the Assouad-Nagata dimension of every minor-closed metric. It is a common generalization of known results about the asymptotic dimension of H-minor free unweighted graphs, about the Assouad-Nagata dimension of complete Riemannian surfaces with finite Euler genus, and about their corollaries on weak diameter coloring of minor-closed families of graphs and asymptotic dimension of minor-excluded groups.

## Dean Bottino : Evaluating Strategies for Overcoming Rituximab (R) Resistance Using a Quantitative Systems Pharmacology (QSP) model of Antibody-Dependent Cell-mediated Cytotoxicity & Phagocytosis (ADCC & ADCP): An Academic/Industrial Collaboration

- Mathematical Biology ( 57 Views )Despite the impressive performance of rituximab (R) containing regimens like R-CHOP in CD20+ Non-Hodgkin’s Lymphoma (NHL), 30-60% of R-naïve NHL patients are estimated to be resistant, and approximately 60% of those patients will not respond to subsequent single agent R treatment. Given that antibody dependent cell mediated cytotoxicity (ADCC) and phagocytosis (ADCP) are thought to be the major mechanisms of action of Rituximab, increasing the activation levels of natural killer (NK) and macrophage (MP) cells may be one strategy for overcoming R resistance.

During (and after) the Fields Institute Industrial Problem Solving Workshop in August 2019, academic participants and industry mentors developed and calibrated to literature data a quantitative systems pharmacology (QSP) model of ADCC/ADCP to interrogate which mechanisms of R resistance could be overcome by increased NK or MP activation, and how much effector cell activation would be required to overcome a given degree and mechanism of R resistance.

This work was motivated by a real-world pharmaceutical drug development question, and the academic-industry interactions during and after the workshop resulted in sharknado plots as well as a published QSP model (presented at American Association of Cancer Research Annual Meeting, 2021) that was able to address some of the key questions around overcoming R resistance. The published model was then incorporated into an in-house QSP model supporting the development of a Takeda investigational drug which is being developed to restore R sensitivity in an R-resistant patient population.